Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Heading off hepatitis C
September 2016
SHARING OPTIONS:

LANGENFELD, Germany & MELBOURNE, Australia—A new team-up is underway between ARTES Biotechnology and Burnet Institute as the organizations take aim at hepatitis C in hopes of developing a novel, effective vaccine to prevent transmission. The partners will combine their technologies to develop a virus-like particle (VLP)-based vaccine that efficiently presents HCV antigens to prevent hepatitis C infection. VLPs will present a novel, modified envelope protein on their surface, which will target the vaccine to dendritic cells to prime the immune system to fight infection.
 
“Access to diagnosis and treatment is limited, especially in endemic countries in Africa and Asia, so there is a strong demand for a safe and low-cost vaccine to prevent hepatitis C infection. This is in line with the aim of the WHO to realize their hepatitis C elimination targets. After out-licensing processes for hepatitis B vaccine production worldwide, ARTES is proud to take the next step together with Burnet Institute in fighting another life-threatening hepatitis infection,” said Dr. Michael Piontek, ARTES' managing director.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.